A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)

PHASE2CompletedINTERVENTIONAL
Enrollment

258

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

July 31, 2013

Conditions
Asthma
Interventions
DRUG

lebrikizumab

subcutaneous dose every 4 weeks

DRUG

lebrikizumab

subcutaneous dose every 4 weeks

DRUG

lebrikizumab

subcutaneous dose every 4 weeks

DRUG

placebo

subcutaneous dose every 4 weeks

Trial Locations (71)

6009

Nedlands

10016

New York

10461

The Bronx

11021

Great Neck

11570

Rockville Centre

17110

Harrisburg

18045

Easton

19013

Upland

19115

Philadelphia

19422

Blue Bell

23233

Henrico

27262

High Point

28401

Wilmington

29303

Spartanburg

29607

Greenville

31406

Savannah

31707

Albany

32308

Tallahassee

32605

Gainesville

32789

Winter Park

33408

North Palm Beach

33613

Tampa

34471

Ocala

35128

Pell City

37909

Knoxville

45231

Cincinnati

53792

Madison

60305

River Forest

64114

Kansas City

66606

Topeka

68123

Bellevue

70006

Metairie

75069

McKinney

75230

Dallas

76018

Arlington

76109

Fort Worth

78224

San Antonio

78251

San Antonio

79925

El Paso

80033

Wheat Ridge

80112

Centennial

80206

Denver

80907

Colorado Springs

85251

Scottsdale

85266

Scottsdale

85712

Tucson

87131

Albuquerque

89106

Las Vegas

89119

Las Vegas

90025

Los Angeles

90048

Los Angeles

91607

Studio City

91786

Upland

92108

San Diego

92270

Rancho Mirage

92691

Mission Viejo

92708

Fountain Valley

92835

Fullerton

92868

Orange

93301

Bakersfield

94558

Napa

94598

Walnut Creek

95819

Sacramento

96814

Honolulu

97035

Lake Oswego

97202

Portland

98105

Seattle

06708

Waterbury

04401

Bangor

97401-7721

Eugene

02865

Warwick

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY